This is the standing evidence sheet for Caribou Biosciences (CRBU): the yardsticks BullScope computes from official SEC filings and market prices. It refreshes whenever a new edition of our research is published, and it is impersonal by design, every reader sees the same page. Nothing here is investment advice; it is the evidence, organized.
The price tag: what buyers pay per dollar of profit
Caribou Biosciences is priced at 11.8× its annual sales (typical for this company over its past decade: 17.8×).
The tape: what the stock itself has done
- Last price: $1.23 (end-of-day market data as of the edition date · methodology) · 57% below its 52-week high
- Past 6 months: -30.9% · past 12 months: -36.3%
- Day-to-day temperament: jumpy (annualized volatility 69%)
The filed record: straight from the annual reports
| Fiscal year | Revenue | Growth | Operating margin | EPS |
|---|---|---|---|---|
| FY2022 | $0.0B | , | -768.2% | $-1.64 |
| FY2023 | $0.0B | +148.9% | -336.6% | $-1.38 |
| FY2024 | $0.0B | -71.0% | -1667.2% | $-1.65 |
| FY2025 | $0.0B | +11.7% | -1329.4% | $-1.59 |
The road ahead: filed results vs published expectations
| FY2023A | FY2024A | FY2025A | FY2026E | FY2027E | |
|---|---|---|---|---|---|
| Net sales ($B) | 0.012 | 0.011 | 0.011 | 0.01 to 0.03 | 0.00 to 0.04 |
| Net sales growth (%) | – | -8 | -7 | -43 | -33 |
| Operating margin (%) | -917 | -1,636 | -1,329 | 500 to 600 | -200 to 500 |
| Diluted EPS ($) | -1.38 | -1.65 | -1.59 | -2.20 to -1.10 | -2.80 to -0.80 |
Columns marked A are actual filed results; E columns are the published consensus ranges the current price is being weighed against.
The four gauges: from the latest edition
Read the full report on Caribou Biosciences in the BullScope Terminal → It opens with this company loaded.
Edition date: 2026-09-26. This page updates when a new edition is published. Sources: SEC EDGAR filings, Nasdaq prices; computed by BullScope’s published methodology.
